3-D Matrix, Ltd. risk profile
26 Normal where most of the sector sits
Measured 21 October 2026 from 7777.T's filed statements. Recomputed nightly.
26 (Normal), driven by Market expectation at 80, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 80 | Acute | Volatile | One-year price volatility — 80.3% |
| Operating pressure | 2 | Contained | Stable | Input-cost exposure — 0.03 |
| Cash conversion | 53 | Elevated | Easing | Cash conversion — 0.10x |
| Leverage and coverage | 4 | Contained | Easing | Current ratio — 3.11x |
| Competitive position | 28 | Normal | Stable | R&D-intensity gap against peers — -22.8 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for 3-D Matrix, Ltd.